Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company's purchase of Sanofi's rare immune ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

Attorneys for the school district say that the legal action is in part due to self-funded insurance plans that has possibly ...

As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...

W ith flu season in full swing, finding effective medications to help with pesky symptoms is key in figuring out how to ...